



[ATS] Improvement in lung function with indacaterol/glycopyrrolate (ind/gly) in patients with moderate to severe COPD from the Us: a subgroup analysis from the Flight1 and Flight2 studies

Kerwin E, Mahler DA, FowlerTaylor A, Maitra S, Banerji D




Introduction.-

IND/GLY 27,5/15,6 μg demonstrated superior improvement in lung function along with rapid onset versus its monocomponents (IND27,5 μg and GLY 15,6 μg) and placebo in patients with moderate-to-severe COPD. **Here we present the lung function data in the subgroup of patients from the US.**



Methods.-

- FLIGHT1 and FLIGHT2 were replicate, 12 week, multi-center. Randomized, double-blind studies that evaluated the safety and efficacy of IND/GLY.
- Lung function was evaluated in terms of the area under the curve up to 12 h for forced expiratory volumen in 1 second (FEV_1 AUC_{0-12H}), TROUGH FEV_1 and peak FEV_1 during 4 hours post dose with IND/GLY versus its monocomponents and placebo.
- Onset of action was evaluated by measuring the improvement in FEV_1 at 5 min post-morning dose on Day1.



Results.- (I)

- Of 2038 patients from the overall pool, 1104 were from the US and included in this analysis (IND/GLY, n=274; IND, n=256; GLY, n=292; placebo, n=278).
- IND/GLY showed superior improvement in lung function with a statistically significant ($p > 0,001$) improvement in $FEV_1 AUC_{0-12H}$ at week 12, compared with placebo, IND and GLY (Table 1).




Results.- (II)

- Improvements in trough FEV₁ and peak FEV₁ were also statistically significant with IND/GLY versus placebo, and its monocomponents at Week 12 (all p<0,001).
- In addition, IND/GLY showed rapid onset of action as indicated by a statistically significant improvement in FEV₁ at 5 min post-dose on Day 1 versus placebo (p<0,001).

Parameters	Treatment difference, mL [LS mean (95% confidence interval)]					
	Day 1			Week 12		
	IND/GLY vs IND	IND/GLY vs GLY	IND/GLY vs Placebo	IND/GLY vs IND	IND/GLY vs GLY	IND/GLY vs Placebo
FEV ₁ AUC 0-12h	99 (76, 121)	48 (26, 70)	181 (159, 203)	118 (81, 156)	111 (75, 147)	267 (230, 305)
Trough FEV ₁ [†]	101 (72, 129)	93 (66, 121)	208 (180, 235)	91 (52, 130)	113 (76, 151)	239 (201, 278)
Peak FEV ₁	102 (79, 125)	31 (9, 54) [‡]	173 (150, 195)	139 (99, 179)	116 (77, 154)	299 (259, 339)
FEV ₁ at 5 min post dose	42 (25, 59)	50 (33, 66)	117 (101, 134)	-	-	-

All p<0.001 except [‡]p=0.006; [†]trough FEV₁ was measured at Day 2 and Day 86



Conclusions.-

- In this post-hoc analysis, IND/GLY b.i.d. Demonstrated superior improvement in lung function with a rapid onset of action compared with monocponents and placebo.

ARC EN EPOC II

Annual Review of Congresses EN EPOC

LO NUEVO EN EPOC PRESENTADO EN ATS, ERS
Y SEPAR CONTADO DE UN MODO DIFERENTE

Madrid, 21 y 22 de Octubre de 2016